Search Results - "Luu, Bernadette W."

Quantitative HLA‐class‐II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A by Diego, Vincent P., Luu, Bernadette W., Hofmann, Marco, Dinh, Long V., Almeida, Marcio, Powell, Jerry S., Rajalingam, Raja, Peralta, Juan M., Kumar, Satish, Curran, Joanne E., Sauna, Zuben E., Kellerman, Roberta, Park, Yara, Key, Nigel S., Escobar, Miguel A., Huynh, Huy, Verhagen, Anne M., Williams‐Blangero, Sarah, Lehmann, Paul V., Maraskovsky, Eugene, Blangero, John, Howard, Tom E.

“…Background Plasma‐derived (pd) or recombinant (r) therapeutic factor VIII proteins (FVIIIs) are infused to arrest/prevent bleeding in patients with hemophilia…”
Get full text

Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products by Jankowski, Wojciech, Park, Yara, McGill, Joseph, Maraskovsky, Eugene, Hofmann, Marco, Diego, Vincent P., Luu, Bernadette W., Howard, Tom E., Kellerman, Roberta, Key, Nigel S., Sauna, Zuben E.

“…The immunogenicity of protein therapeutics is an important safety and efficacy concern during drug development and regulation. Strategies to identify…”
Get full text

Gene-Centric Association Scans of Pleiotropic Immune-Mediated Disease Genes in the PATH Study Identify Novel Determinants of Factor VIII Inhibitor Risk in Hemophilia-A Patients and Confirm Race as an Independent Predictor by Bouls, Ruayda, Almeida, Marcio A., Diego, Vincent P., Luu, Bernadette W., Rajalingam, Raja, Ameri, Afshin, Viel, Kevin R., Chitlur, Meera, Kim, Benjamin, Escobar, Miguel A., Williams-Blangero, Sarah, Kasper, Carol K., Almasy, Laura, Blangero, John, Howard, Tom E.

“…Hemophilia-A (HA) is caused by heterogeneous loss-of-function factor (F) VIII gene ( F8) mutations and deficiencies in plasma FVIII coagulant activity…”
Get full text

Results from an Association-Scan of the Extended MHC-Class-II Region Using Novel Association-Based Statistical Methods Establish That DQ Allotypes and Race Independently Influence the Risk of Factor VIII Inhibitor Development in Hemophilia-A Patients by Ibarra, Paola, Almeida, Marcio A., Diego, Vincent P., Luu, Bernadette W., Viel, Kevin R., Rajalingam, Raja, Ameri, Afshin, Chitlur, Meera, Kim, Benjamin, Castillo, Grecia, Powell, Jerry S., Peralta, Juan M., Escobar, Miguel A., Williams-Blangero, Sarah, Blangero, John, Kasper, Carol K., Almasy, Laura, Howard, Tom E.

“…Hemophilia-A (HA) is caused by heterogeneous factor (F) VIII gene ( F8) mutations, variably deficient plasma FVIII activity and reduced to absent…”
Get full text

The G505A Nonsynonymous Single-Nucleotide Polymorphism (SNP) in TAFI, the Gene Encoding Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Is Pleiotropically Associated with TAFI Antigen Levels and Coronary Heart Disease (CHD) in Mexican Americans of South Texas by Jhaveri, Shuchita, Diego, Vincent P., Nguyen, Hoang Anh Thi, Kumar, Satish, Almeida, Marcio A., Peralta, Juan M, Curran, Joanne E., Luu, Bernadette W., Lehman, Donna M., DeFronzo, Ralph A, Escobar, Miguel A., Williams-Blangero, Sarah, Duggirala, Ravi, Powell, Jerry S., Almasy, Laura, Blangero, John, Howard, Tom E.

“…Studies have reported that the G505A nonsynonymous (ns)-SNP encoding the Ala147Thr amino acid substitution in TAFI, is associated with a reduction in risk of…”
Get full text

The Factor II (FII) Expression Quantitative Trait Locus (eQTL) Prothrombin G20210A Is Pleiotropically Associated with Plasma Fibrinogen Levels and Has a Profound Effect on Obesity in Mexican Americans of South Texas by Nguyen, Hoang Anh Thi, Diego, Vincent P., Jhaveri, Shuchita, Almeida, Marcio A., Kumar, Satish, Peralta, Juan M, Curran, Joanne E., Luu, Bernadette W., Lehman, Donna M., DeFronzo, Ralph A, Escobar, Miguel A., Williams-Blangero, Sarah, Duggirala, Ravi, Powell, Jerry S., Almasy, Laura, Blangero, John, Howard, Tom E.

“…The literature on risk factors for venous thromboembolism (VTE) is replete with complex combinations of genetic and environmental determinants. Here we apply…”
Get full text

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses by Howard, Tom E., Luu, Bernadette W., Hofmann, Marco, Almeida, Marcio A., Kumar, Satish, Dinh, Long V., Mead, Henry, Powell, Jerry S., Escobar, Miguel A., Rajalingam, Raja, Williams-Blangero, Sarah, Blangero, John, Eugene, Maraskovsky, Diego, Vincent P.

“…Background: Patients with the X-linked bleeding disorder hemophilia A have impaired blood clotting due to deficient or absent factor VIII (FVIII) coagulant…”
Get full text

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes by Diego, Vincent P., Luu, Bernadette W., Movva, Hari, Hofmann, Marco, Almeida, Marcio A., Dinh, Long V., Powell, Jerry S., Rajalingam, Raja, Peralta, Juan M, Mead, Henry, Kumar, Satish, Curran, Joanne E., Escobar, Miguel A., Williams-Blangero, Sarah, Maraskovsky, Eugene, Blangero, John, Howard, Tom E.

“…The role played by N-linked glycans (NLGs) in the immunogenicity of therapeutic Factor VIII (tFVIII) proteins is poorly understood. Our study addresses this…”
Get full text

Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A by Dinh, Long V., Fine, Eli, Ameri, Afshin, Luu, Bernadette W., Kumar, Satish, Diego, Vincent P., Curran, Joanne E., Peralta, Juan M, Mead, Henry, Escobar, Miguel A., Williams-Blangero, Sarah, Blangero, John, Powell, Jerry S., Nichols, Timothy C., Hebbel, Robert P., Howard, Tom E.

“…A heterogeneous collection of >1500 distinct causative factor (F) VIII gene (F8) mutations have been identified thus far in unrelated severe Hemophilia A (HA)…”
Get full text

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A by Diego, Vincent P., Luu, Bernadette W., Garza, Alexis, Hofmann, Marco, Almeida, Marcio A., Powell, Jerry S., Dinh, Long V., Rajalingam, Raja, Peralta, Juan M, Kumar, Satish, Fine, Eli, Curran, Joanne E., Escobar, Miguel A., Williams-Blangero, Sarah, Maraskovsky, Eugene, Blangero, John, Howard, Tom E.

“…The HLA haplotype DRB1*15:01/DQB1*06:02 has been shown to be associated with the development of inhibitory antibodies (“inhibitors”) against therapeutic FVIII…”
Get full text

The Role of Class II Human Leukocyte Antigens (cII-HLAs) in Determining the Immunogenic Potential of Therapeutic Factor VIII Proteins in Hemophilia Patients: The “Gate Keeper” Hypothesis by Diego, Vincent P., Luu, Bernadette W., Hofmann, Marco, Almeida, Marcio A., Hernandez, Jose Antonio G., Peralta, Juan, Curran, Joanne, Powell, Jerry S., Rajalingam, Raja, Dinh, Long V., Williams-Blangero, Sarah, Escobar, Miguel A, Maraskovsky, Eugene, Blangero, John, Howard, Tom E.

“…The development of neutralizing antibodies-termed “inhibitors”-to infused therapeutic (t) factor VIII proteins (tFVIIIs) is the most serious obstacle to…”
Get full text

Genetics of Factor VIII Inhibitor Development in Hemophilia Patients: Novel Statistical Approaches in the PATH Study by Diego, Vincent P., Almeida, Marcio A., Luu, Bernadette W., Haack, Karin, Chitlur, Meera B., Ameri, Afshin, Dinh, Long V., Rajalingam, Raja, Powell, Jerry S., Blangero, John, Almasy, Laura, Cole, Shelley, Howard, Tom E.

“…Here we apply state-of-the-art statistical genetic approaches toward investigating the genetic architecture of factor VIII (FVIII) inhibitor (FEI) development…”
Get full text

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies (“Inhibitors”) Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study by Diego, Vincent P., Luu, Bernadette W., Ameri, Afshin, Chitlur, Meera B., Almeida, Marcio A., Haack, Karin, Kumar, Satish, Dinh, Long V., Mead, Henry, Powell, Jerry S., Escobar, Miguel A., Rajalingam, Raja, Williams-Blangero, Sarah, Kasper, Carol K., Almasy, Laura, Cole, Shelley, Blangero, John, Howard, Tom E.

“…The development of inhibitors against tFVIIIs represents a serious impediment to efficacious management of bleeding episodes in patients with hemophilia A…”
Get full text

A Novel Biomarker for Inhibitor Risk Prediction-the HLA-II Bound and Unbound Components of FVIII Derived Peptides-Reveals a Protective Influence for N-Linked Glycosylation by Viel, Kevin R., Hofmann, Marco, Zollner, Sabine, Luu, Bernadette W., Raja, Rajalingam, Powell, Jerry Sherman, Maraskovsky, Eugene, Howard, Tom E.

“…Introduction: Factor (F)VIII immunogenicity is the main obstacle to both successfully treating hemophilia and receiving FDA approval for new therapeutics…”
Get full text

Characterization of the HLA-Class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome By FVIII Domain and HLAcII Isomer by Almeida, Marcio, Diego, Vincent P., Luu, Bernadette W., Hofmann, Marco, Hernandez, Jose Antonio G., Peralta, Juan, Curran, Joanne, Escobar, Miguel A, Raja, Rajalingam, Dinh, LV, Powell, Jerry S., Williams-Blangero, Sarah, Blangero, John, Maraskovsky, Eugene, Howard, Tom

“…Background: Hemophilia A (HA) is caused by F8 mutations and resultant plasma deficiencies in FVIII activity. While bleeding can be arrested by infusing…”
Get full text

P059 Analysis of HLAcII peptidomes presented by dendritic cells (DCs) from healthy donors and hemophilia-A (HA) patients with or without factor VIII (FVIII) inhibitors after ex vivo administration of different therapeutic FVIII proteins (tFVIIIs) by Howard, Tom E., Diego, Vincent P., Hofmann, Marco, Almeida, Marcio, Luu, Bernadette W., Dinh, Long V., Rajalingam, Raja, Escobar, Miguel, Curran, Joanne, Williams-Blangero, Sarah, Powell, Jerry, Blangero, John, Maraskovsky, Eugene, Key, Nigel S., Sauna, Zuben E.

“…T cells specific for tFVIIIs in HA patients can induce neutralizing FVIII antibodies called inhibitors. DCs that present tFVIII derived peptides in their…”
Get full text